Plasmid DNA Manufacturing Market Report 2026

The plasmid dna manufacturing market size has grown exponentially in recent years. It will grow from $2.89 billion in 2025 to $3.58 billion in 2026 at a compound annual growth rate (CAGR) of 23.6%. The growth in the historic period can be attributed to increasing use of plasmid dna in research applications, expansion of molecular cloning activities, growth of preclinical therapeutic development, rising investments in biotechnology research, improved bacterial fermentation techniques.

The plasmid dna manufacturing market size is expected to see exponential growth in the next few years. It will grow to $7.64 billion in 2030 at a compound annual growth rate (CAGR) of 20.9%. The growth in the forecast period can be attributed to increasing demand for dna-based vaccines, rising investments in gene and cell therapy pipelines, expansion of commercial-scale plasmid manufacturing, growing focus on regulatory-compliant production, increasing adoption of advanced purification technologies. Major trends in the forecast period include increasing demand for gmp-grade plasmid dna production, rising adoption of automated bioprocessing systems, growing use of plasmid dna in gene therapy applications, expansion of large-scale manufacturing capacities, enhanced focus on high-purity dna production.

The increasing acceptance of gene therapy is expected to drive the growth of the plasmid DNA manufacturing market going forward. Gene therapy is a medical approach that involves altering or manipulating an individual’s genes to treat or prevent diseases. The adoption of gene therapy is rising due to advances in genetic engineering technologies, increased investment in research and development, successful clinical trial outcomes, and the growing prevalence of genetic disorders, all of which underscore its potential to deliver long-term or permanent treatments. Plasmid DNA manufacturing plays a critical role in gene therapy by producing the vectors required to deliver therapeutic genes into target cells, enabling the treatment of genetic conditions. For instance, according to the American Society of Gene & Cell Therapy, a US-based nonprofit medical and scientific organization, the number of gene therapies in Phase III clinical trials increased by 10% in the third quarter of 2023, marking the first quarterly rise since the third quarter of 2022. Therefore, the growing acceptance of gene therapy is fueling the growth of the plasmid DNA manufacturing market.

Major companies operating in the plasmid DNA manufacturing market are focusing on the development of advanced bioprocessing technologies to improve the efficiency, scalability, and quality of plasmid DNA production. These innovations are intended to optimize manufacturing workflows, lower production costs, and ensure that plasmid DNA complies with strict regulatory requirements for therapeutic use. For instance, in January 2023, Charles River Laboratories, a US-based pharmaceutical company, introduced the eXpDNA platform, which is designed for the efficient production and purification of high-quality plasmid DNA. The platform incorporates advanced bioprocessing technologies, scalable manufacturing approaches, and comprehensive quality control systems to produce plasmid DNA that meets rigorous standards for clinical and therapeutic applications. The eXpDNA platform is widely used in gene therapy, DNA vaccine development, and other biopharmaceutical applications that require high yield, purity, and consistency.

In March 2023, Sartorius Stedim Biotech, a Germany-based provider of bioprocess solutions for the life sciences industry, acquired Polyplus for approximately US$2.6 billion (€2.4 billion). Through this acquisition, Sartorius seeks to enhance its plasmid DNA manufacturing capabilities by incorporating Polyplus’s GMP-grade plasmid DNA and transfection reagents, thereby strengthening its offerings for viral vector and gene therapy production. Polyplus is a France-based company that supplies GMP-grade plasmid DNA and nucleic acid delivery reagents for gene and cell therapy applications.

Major companies operating in the plasmid dna manufacturing market are Thermo Fisher Scientific Inc., Eurofins Genomics LLC, Catalent Inc., Charles River Laboratories, Recipharm AB, Kaneka Corp., Genscript Biotech Corporation, Aldevron LLC, Genewiz, OriGene Technologies, Celonic AG, Creative Biogene, Cellectis, Synbio Technologies, VectorBuilder Inc., Altogen Biosystems, Andelyn Biosciences, AGC Biologics, VGXI, GeneCopoeia, PlasmidFactory GmbH & Co. KG, Akron Biotech, PackGene Biotech Inc.

North America was the largest region in the plasmid DNA manufacturing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the plasmid dna manufacturing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the plasmid dna manufacturing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the plasmid DNA manufacturing market by increasing costs of imported bioreactors, fermentation equipment, chromatography systems, reagents, and single-use consumables. Biopharmaceutical manufacturers in North America and Europe are most affected due to reliance on imported bioprocessing equipment, while Asia-Pacific faces cost pressures on export-oriented production. These tariffs are increasing capital expenditure and extending facility expansion timelines. However, they are also encouraging domestic manufacturing of bioprocess equipment, regional supply chain development, and investments in localized plasmid DNA production infrastructure.

The plasmid dna manufacturing market research report is one of a series of new reports that provides plasmid dna manufacturing market statistics, including plasmid dna manufacturing industry global market size, regional shares, competitors with a plasmid dna manufacturing market share, detailed plasmid dna manufacturing market segments, market trends and opportunities, and any further data you may need to thrive in the plasmid dna manufacturing industry. This plasmid dna manufacturing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Plasmid deoxyribonucleic acid (DNA) manufacturing involves the production of large volumes of plasmid DNA molecules for use in a range of biotechnological applications, including gene therapy, molecular cloning, and recombinant protein production. The process includes cultivating bacterial cells that carry the target plasmid DNA, followed by purification steps to separate the plasmid DNA from other cellular materials.

The primary grades of plasmid DNA manufacturing include research and development grade and good manufacturing practice (GMP) grade. Research and development grade plasmid DNA is mainly produced for laboratory research and early-stage development activities. It is utilized across multiple development stages, including pre-clinical therapeutics, clinical therapeutics, and marketed therapeutics, for treating infectious diseases, cancer, genetic disorders, and other conditions. Plasmid DNA plays a critical role in applications such as deoxyribonucleic acid (DNA) vaccines, cell and gene therapy, immunotherapy, and other related uses.

The plasmid DNA manufacturing market consists of revenues earned by entities by providing services such as plasmid design, construction, production, purification, quality control, customization, storage, shipping, and regulatory support. The market value includes the value of related goods sold by the service provider or included within the service offering. The plasmid DNA manufacturing market also includes sales of bioreactors, centrifuges, incubators, chromatography systems, freeze dryers, electrophoresis systems, and microscopes. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.